PTK2B/Pyk2 overexpression improves a mouse model of Alzheimer's disease

Abstract Pyk2 is a Ca2+‐activated non‐receptor tyrosine kinase enriched in forebrain neurons and involved in synaptic regulation. Human genetic studies associated PTK2B, the gene coding Pyk2, with risk for Alzheimer's disease (AD). We previously showed that Pyk2 is important for hippocampal function, plasticity, and spine structure. However, its potential role in AD is unknown. To address this question we used human brain samples and 5XFAD mice, an amyloid mouse model of AD expressing mutated human amyloid precursor protein and presenilin1. In the hippocampus of 5XFAD mice and in human AD patients' cortex and hippocampus, Pyk2 total levels were normal. However, Pyk2 Tyr‐402 phosphorylation levels, reflecting its autophosphorylation‐dependent activity, were reduced in 5XFAD mice at 8 months of age but not 3 months. We crossed these mice with Pyk2−/− mice to generate 5XFAD animals devoid of Pyk2. At 8 months the phenotype of 5XFAD x Pyk2−/− double mutant mice was not different from that of 5XFAD. In contrast, overexpression of Pyk2 in the hippocampus of 5XFAD mice, using adeno‐associated virus, rescued autophosphorylated Pyk2 levels and improved synaptic markers and performance in several behavioral tasks. Both Pyk2−/− and 5XFAD mice showed an increase of potentially neurotoxic Src cleavage product, which was rescued by Pyk2 overexpression. Manipulating Pyk2 levels had only minor effects on A&bgr; plaques, which were slightly decreased in hippocampus CA3 region of double mutant mice and increased following overexpression. Our results show that Pyk2 is not essential for the pathogenic effects of human amyloidogenic mutations in the 5XFAD mouse model. However, the slight decrease in plaque number observed in these mice in the absence of Pyk2 and their increase following Pyk2 overexpression suggest a contribution of this kinase in plaque formation. Importantly, a decreased function of Pyk2 was observed in 5XFAD mice, indicated by its decreased autophosphorylation and associated Src alterations. Overcoming this deficit by Pyk2 overexpression improved the behavioral and molecular phenotype of 5XFAD mice. Thus, our results in a mouse model of AD suggest that Pyk2 impairment may play a role in the symptoms of the disease. HighlightsPyk2 gene (PTK2B) was reported associated with risk for Alzheimer's disease.Pyk2 protein levels were not altered in hippocampus of AD patients or mouse 5XFAD model.Pyk2 autophosphorylation was decreased in hippocampus of 5XFAD mice.Crossing Pyk2 KO and 5XFAD mice did not alter the severity of the disease.Pyk2 overexpression improved behavioral and histological alterations in 5XFAD mice.

[1]  W. Thies,et al.  2013 Alzheimer's disease facts and figures , 2013, Alzheimer's & Dementia.

[2]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[3]  S. Strittmatter,et al.  Disease-modifying benefit of Fyn blockade persists after washout in mouse Alzheimer's model , 2018, Neuropharmacology.

[4]  J. Hell,et al.  Postsynaptic Clustering and Activation of Pyk2 by PSD-95 , 2010, The Journal of Neuroscience.

[5]  A. Scaloni,et al.  Platelet-derived Growth Factor Induces the β-γ-Secretase-mediated Cleavage of Alzheimer's Amyloid Precursor Protein through a Src-Rac-dependent Pathway* , 2003, The Journal of Biological Chemistry.

[6]  B. Strooper,et al.  The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes , 2012, Nature Neuroscience.

[7]  C. Bouras,et al.  The PKR Activator PACT Is Induced by Aβ: Involvement in Alzheimer's Disease , 2012, Brain pathology.

[8]  L. Mucke,et al.  Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. , 2012, Cold Spring Harbor perspectives in medicine.

[9]  C. Lipinski,et al.  Targeting Pyk2 for therapeutic intervention , 2010, Expert opinion on therapeutic targets.

[10]  S. Strittmatter,et al.  Oligomers of Amyloid β Prevent Physiological Activation of the Cellular Prion Protein-Metabotropic Glutamate Receptor 5 Complex by Glutamate in Alzheimer Disease* , 2016, The Journal of Biological Chemistry.

[11]  Jerry R. Thomas,et al.  Multisite tyrosine phosphorylation of the N‐terminus of Mint1/X11α by Src kinase regulates the trafficking of amyloid precursor protein , 2016, Journal of neurochemistry.

[12]  M. Sheng,et al.  Proline-Rich Tyrosine Kinase 2 Regulates Hippocampal Long-Term Depression , 2010, The Journal of Neuroscience.

[13]  J. Becker,et al.  Genetic determinants of disease progression in Alzheimer's disease. , 2014, Journal of Alzheimer's disease : JAD.

[14]  E. Mandelkow,et al.  Biochemistry and cell biology of tau protein in neurofibrillary degeneration. , 2012, Cold Spring Harbor perspectives in medicine.

[15]  D. Alkon,et al.  PKC ε Activation Prevents Synaptic Loss, Aβ Elevation, and Cognitive Deficits in Alzheimer's Disease Transgenic Mice , 2011, The Journal of Neuroscience.

[16]  Margaret A. Pericak-Vance,et al.  Genome-Wide Association Meta-analysis of Neuropathologic Features of Alzheimer's Disease and Related Dementias , 2014, PLoS genetics.

[17]  S. Lipton,et al.  Oligomeric Aβ-induced synaptic dysfunction in Alzheimer’s disease , 2014, Molecular Neurodegeneration.

[18]  M. Pallàs,et al.  Epigenetic mechanisms underlying cognitive impairment and Alzheimer disease hallmarks in 5XFAD mice , 2016, Aging.

[19]  H. Soininen,et al.  Functional screening of Alzheimer risk loci identifies PTK2B as an in vivo modulator and early marker of Tau pathology , 2016, Molecular Psychiatry.

[20]  H. Vinters,et al.  Emerging concepts in Alzheimer's disease. , 2015, Annual review of pathology.

[21]  Yu Tian Wang,et al.  A balance between excitatory and inhibitory synapses is controlled by PSD-95 and neuroligin. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Girault,et al.  Depolarization Activates ERK and Proline-rich Tyrosine Kinase 2 (PYK2) Independently in Different Cellular Compartments in Hippocampal Slices* , 2005, Journal of Biological Chemistry.

[23]  J. Hell,et al.  Striatal-enriched Protein-tyrosine Phosphatase (STEP) Regulates Pyk2 Kinase Activity* , 2012, The Journal of Biological Chemistry.

[24]  George Perry,et al.  Reexamining Alzheimer's disease: evidence for a protective role for amyloid-beta protein precursor and amyloid-beta. , 2009, Journal of Alzheimer's disease : JAD.

[25]  J. Girault,et al.  FAK+ and PYK2/CAKβ, two related tyrosine kinases highly expressed in the central nervous system: similarities and differences in the expression pattern , 1999, The European journal of neuroscience.

[26]  M. Giordano,et al.  Beta‐amyloid protein (25–35) disrupts hippocampal network activity: Role of Fyn‐kinase , 2009, Hippocampus.

[27]  Mary Miu Yee Waye,et al.  Polygenic Analysis of Late-Onset Alzheimer’s Disease from Mainland China , 2015, PloS one.

[28]  J. Aten,et al.  Measurement of co‐localization of objects in dual‐colour confocal images , 1993, Journal of microscopy.

[29]  J. Pozueta,et al.  Synaptic changes in Alzheimer’s disease and its models , 2013, Neuroscience.

[30]  J. Girault,et al.  Pyk2 modulates hippocampal excitatory synapses and contributes to cognitive deficits in a Huntington's disease model , 2017, Nature Communications.

[31]  Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. , 2009, Cell.

[32]  Kristine Yaffe,et al.  Gene-based aggregate SNP associations between candidate AD genes and cognitive decline , 2016, AGE.

[33]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[34]  S. Strittmatter,et al.  Fyn inhibition rescues established memory and synapse loss in Alzheimer mice , 2015, Annals of neurology.

[35]  Bernardo L Sabatini,et al.  Synapses and Alzheimer's disease. , 2012, Cold Spring Harbor perspectives in biology.

[36]  M. Tansey,et al.  Peripheral administration of the soluble TNF inhibitor XPro1595 modifies brain immune cell profiles, decreases beta-amyloid plaque load, and rescues impaired long-term potentiation in 5xFAD mice , 2017, Neurobiology of Disease.

[37]  J. Roder,et al.  CAKβ/Pyk2 Kinase Is a Signaling Link for Induction of Long-Term Potentiation in CA1 Hippocampus , 2001, Neuron.

[38]  S. Lev,et al.  A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP kinase activation , 1996, Nature.

[39]  A. Hill,et al.  A Truncated Fragment of Src Protein Kinase Generated by Calpain-mediated Cleavage Is a Mediator of Neuronal Death in Excitotoxicity* , 2013, The Journal of Biological Chemistry.

[40]  Jürgen Götz,et al.  Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models , 2010, Cell.

[41]  John W. Gilbert,et al.  Cellular Prion Protein Mediates Impairment of Synaptic Plasticity by Amyloid-β Oligomers , 2009, Nature.

[42]  A. Maelicke,et al.  Galantamine Slows Down Plaque Formation and Behavioral Decline in the 5XFAD Mouse Model of Alzheimer’s Disease , 2014, PloS one.

[43]  M. Ohno,et al.  Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation , 2006, The Journal of Neuroscience.

[44]  Nick C Fox,et al.  Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease , 2013, Nature Genetics.

[45]  J. Girault,et al.  Pyk2 is essential for astrocytes mobility following brain lesion , 2016, Glia.

[46]  Shin-Young Park,et al.  RAFTK/Pyk2 Activation Is Mediated by Trans-acting Autophosphorylation in a Src-independent Manner* , 2004, Journal of Biological Chemistry.

[47]  O. Garaschuk,et al.  Neuroinflammation in Alzheimer's disease , 2015, The Lancet Neurology.

[48]  T. Sacktor,et al.  Postsynaptic degeneration as revealed by PSD-95 reduction occurs after advanced Aβ and tau pathology in transgenic mouse models of Alzheimer’s disease , 2011, Acta Neuropathologica.

[49]  J. Girault,et al.  How to awaken your nanomachines: Site-specific activation of focal adhesion kinases through ligand interactions. , 2015, Progress in biophysics and molecular biology.

[50]  J. Girault,et al.  Differential Regulation of Proline-rich Tyrosine Kinase 2/Cell Adhesion Kinase β (PYK2/CAKβ) and pp125FAK by Glutamate and Depolarization in Rat Hippocampus* , 1996, The Journal of Biological Chemistry.

[51]  J. Girault,et al.  FAK and PYK2/CAKβ in the nervous system: a link between neuronal activity, plasticity and survival? , 1999, Trends in Neurosciences.

[52]  P. Greengard,et al.  Inhibitor of the Tyrosine Phosphatase STEP Reverses Cognitive Deficits in a Mouse Model of Alzheimer's Disease , 2014, PLoS biology.

[53]  Sascha Weggen,et al.  Alzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X , 2015, Scientific Reports.

[54]  Robert A. H. White,et al.  Identification and Characterization of a Novel Related Adhesion Focal Tyrosine Kinase (RAFTK) from Megakaryocytes and Brain (*) , 1995, The Journal of Biological Chemistry.

[55]  Terukatsu Sasaki,et al.  Cloning and Characterization of Cell Adhesion Kinase β, a Novel Protein-tyrosine Kinase of the Focal Adhesion Kinase Subfamily (*) , 1995, The Journal of Biological Chemistry.

[56]  E. Peles,et al.  Protein tyrosine kinase PYK2 involved in Ca2+-induced regulation of ion channel and MAP kinase functions , 1995, Nature.

[57]  Y. Matsuoka,et al.  Fyn knock-down increases Aβ, decreases phospho-tau, and worsens spatial learning in 3×Tg-AD mice , 2012, Neurobiology of Aging.

[58]  B. Jenkins,et al.  Combination therapy in a transgenic model of Alzheimer's disease , 2013, Experimental Neurology.

[59]  K. Reymann,et al.  Behavioral and EEG changes in male 5xFAD mice , 2014, Physiology & Behavior.

[60]  J. Götz,et al.  Somatodendritic accumulation of Tau in Alzheimer's disease is promoted by Fyn‐mediated local protein translation , 2017, The EMBO journal.